1. Home
  2. FHI vs NAMS Comparison

FHI vs NAMS Comparison

Compare FHI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FHI
  • NAMS
  • Stock Information
  • Founded
  • FHI 1955
  • NAMS 2019
  • Country
  • FHI United States
  • NAMS Netherlands
  • Employees
  • FHI N/A
  • NAMS N/A
  • Industry
  • FHI Investment Managers
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • FHI Finance
  • NAMS Health Care
  • Exchange
  • FHI Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • FHI 3.4B
  • NAMS 2.7B
  • IPO Year
  • FHI N/A
  • NAMS N/A
  • Fundamental
  • Price
  • FHI $37.76
  • NAMS $18.57
  • Analyst Decision
  • FHI Hold
  • NAMS Strong Buy
  • Analyst Count
  • FHI 6
  • NAMS 7
  • Target Price
  • FHI $42.00
  • NAMS $41.33
  • AVG Volume (30 Days)
  • FHI 694.4K
  • NAMS 618.3K
  • Earning Date
  • FHI 01-30-2025
  • NAMS 03-04-2025
  • Dividend Yield
  • FHI 3.28%
  • NAMS N/A
  • EPS Growth
  • FHI N/A
  • NAMS N/A
  • EPS
  • FHI 3.23
  • NAMS N/A
  • Revenue
  • FHI $1,632,093,000.00
  • NAMS $33,594,000.00
  • Revenue This Year
  • FHI $7.04
  • NAMS $131.53
  • Revenue Next Year
  • FHI $4.41
  • NAMS N/A
  • P/E Ratio
  • FHI $11.69
  • NAMS N/A
  • Revenue Growth
  • FHI 1.40
  • NAMS 78.77
  • 52 Week Low
  • FHI $31.24
  • NAMS $15.19
  • 52 Week High
  • FHI $43.92
  • NAMS $27.29
  • Technical
  • Relative Strength Index (RSI)
  • FHI 35.09
  • NAMS 29.65
  • Support Level
  • FHI $37.70
  • NAMS $18.88
  • Resistance Level
  • FHI $38.79
  • NAMS $20.46
  • Average True Range (ATR)
  • FHI 0.71
  • NAMS 1.11
  • MACD
  • FHI -0.03
  • NAMS -0.09
  • Stochastic Oscillator
  • FHI 4.20
  • NAMS 5.84

About FHI Federated Hermes Inc.

Federated Hermes provides asset-management services for institutional and individual investors. The firm had $800 billion in managed assets at the end of September 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (74%) funds. The firm's cash-management operations are expected to generate around 51% of Federated's revenue this year, compared with 29%, 12%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (65% of AUM), institutional investors (26%), and international clients (9%).

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: